Drug Development Unit, Division of Cancer Therapeutics, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.
Curr Oncol Rep. 2012 Apr;14(2):111-9. doi: 10.1007/s11912-012-0225-0.
The fibroblast growth factor (FGF) signaling pathway is implicated as a key driver of tumor progression and growth via the dysregulation of cell proliferation, differentiation, survival, and angiogenesis in multiple tumor types. In addition, it may serve as a mechanism of resistance to antivascular endothelial growth factor targeted therapy. As such this pathway has emerged as a relevant therapeutic target, and several agents that can inhibit or modulate its signaling are in various stages of development. This review will summarize the current clinical status of agents targeting FGF receptors. In addition, strategies to accelerate the clinical development of these targeted agents will be presented.
成纤维细胞生长因子 (FGF) 信号通路通过调节多种肿瘤类型中的细胞增殖、分化、存活和血管生成，被认为是肿瘤进展和生长的关键驱动因素。此外，它可能是抗血管内皮生长因子靶向治疗耐药的机制。因此，该通路已成为一个相关的治疗靶点，几种能够抑制或调节其信号的药物处于不同的开发阶段。这篇综述将总结目前针对 FGF 受体的药物的临床现状。此外，还将提出加速这些靶向药物临床开发的策略。
